Floatz logo

TACROLIMUS

Skin Neoplasms

Wyeth is now a wholly owned subsidiary of PfizerSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Skin Neoplasms cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Nivolumab
UNICANCER
Phase 2B
TRASTUZUMAB
Cancer Research UK
Phase 2/3B
Difluoromethylornithine
University of Wisconsin, Madison
Phase 2B

View all 24 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →